Valirx (VAL)


Latest News

Holding(s) in Company

RNS Number: 9770W ValiRx PLC 20 November 2017 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Valirx PLC 1b. Please ...

Yorkville CLN Conversion

RNS Number: 6282W ValiRx PLC 15 November 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Loan Note Conversion and Issue of Equity London, UK ., 15 November 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines ...

ValiRx obtains new US patent allowance

ValiRx said its joint venture with Tangent Reprofiling has obtained a new US patent allowance. The clinical stage therapeu...

Notification of US Patent Allowance

RNS Number: 2470T ValiRx PLC 11 October 2017 VALIRX PLC ("ValiRx", the "Company" or the "Group") NOTIFICATION OF US PATENT ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL401 London, UK ., 11 October 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to report that ValiSeek Limited ("ValiSeek"), the join...

All News

20-11-17Holding(s) in CompanyRNS
15-11-17Yorkville CLN ConversionRNS
11-10-17ValiRx obtains new US patent allowanceStockMarketWire
11-10-17Notification of US Patent AllowanceRNS
05-10-17Holding(s) in CompanyRNS
02-10-17Total Voting RightsRNS
28-09-17ValiRx cancer treatment JV progressing wellStockMarketWire
28-09-17ValiSeek Clinical Development UpdateRNS
28-09-17ValiRx - Valiseek Clinical Development UpdateBRR Media
27-09-17Holding(s) in CompanyRNS
26-09-17ValiRx interim loss narrowsStockMarketWire
26-09-17Half-year ReportRNS
26-09-17ValiRx - Half-year Report 2017BRR Media
20-09-17VAL201 updateRNS
19-09-17Issue of EquityRNS
13-09-17Hardman Research: GeneICE and VAL101 progressRNS
07-09-17ValiRx reports good progress in developing GeneICE technology platformStockMarketWire
07-09-17GeneICE & VAL101 UpdateRNS
07-09-17ValiRx - GeneICE & VAL101 UpdateBRR Media
11-08-17Convertible Loan FacilityRNS
02-08-17Conversion of Loan NoteRNS
28-07-17ValiRx signs first product licensing agreementStockMarketWire
28-07-17Licencing AgreementRNS
22-06-17Formation of & Appointments to an Advisory BoardRNS
15-06-17ValiSeek Development Update - Recruitment ClosesRNS
15-06-17ValiRx - ValiSeek Clinical Development UpdateBRR Media
01-06-17ValiRx updates on Yorkville CLN ConversionStockMarketWire
01-06-17Yorkville CLN ConversionRNS
31-05-17Hardman Research:Developing novel cancer therapiesRNS
30-05-17All resolutions passed at AGM of ValiRxStockMarketWire
30-05-17Result of AGMRNS
24-05-17ValiSeek's patent allowed in AustraliaStockMarketWire
08-05-17Broker Forecast - Beaufort Securities issues a broker note on ValiRx PLCStockMarketWire
08-05-17ValiRx - Final Results BRR Media
05-05-17Notice of AGMRNS
05-05-17ValiRx widens FY pretax loss from continuing ops.StockMarketWire
05-05-17Final ResultsRNS
27-04-17Re: SHARES Magazine Supplement on ValiRx websiteRNS
19-04-17Change of Registered OfficeRNS

RSS feeds

  • Editorial news feed for LSE:VAL Editorial
  • Regulatory news feed for LSE:VAL Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account